Hemab Therapeutics Holdings Inc
COAGHealthcare|Biotechnology|USA
$38.09
+0.83 (+2.23%)
Clinical Trials (8)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06754852 A Study Assessing HMB-002 in Participants With Von Willebrand Disease | Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1 | P1P2 | Recruiting | 108 | Open-label | HMB-002 (Part A), HMB-002 (Part B), HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US) |
| NCT06211634 A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia | Glanzmann Thrombasthenia | P1P2 | Active | 57 | Open-label | HMB-001 |
| NCT07347249 A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency | Congenital Factor VII Deficiency | P2 | Recruiting | 18 | Open-label | Sutacimig, Sutacimig |
| NCT04398628 ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders | Hematologic Disorder, Bleeding Disorder | Recruiting | 3,000 | — | — | |
| NCT06610201 A Study of Bleeding and Treatment in Participants With Von Willebrand Disease | Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1 | Recruiting | 200 | — | — | |
| NCT05315232 The Experiences of People Who Live With Glanzmanns Thrombasthenia. | Glanzmann Thrombasthenia | Completed | 122 | — | — | |
| NCT06064643 The Lived Experience of People With Von Willebrand Disease | Von Willebrand Diseases | Completed | 611 | — | — | |
| NCT05607602 Are Uterine Fibroids Pro-thrombotic? | Leiomyoma, Uterine, Thrombosis | Unknown | 105 | — | — |